Lilly misses sales forecast by $800M, lowers revenue guidance for the year

Kyle LaHucik

Senior Reporter

Eli Lilly lowered the top end of its full-year revenue guidance by $600 million on Wednesday, as its third-quarter sales were about $800 million below …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Lilly misses sales forecast by $800M, lowers revenue guidance for the year

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

A startup backed by Nobel winner David Baker takes an AI twist on antibodies

Biogen signs molecular glue deal, raises yearly projections

GSK remains ‘very confident’ in RSV vaccine amid competition, sales slump

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Sage, Biogen won't pursue major depression approval for postpartum pill

Axonis snags $115M to test oral drugs for epilepsy and neuropathic pain

Lil­ly miss­es sales fore­cast by $800M, low­ers rev­enue guid­ance for the year

Senior Reporter

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Lilly misses sales forecast by $800M, lowers revenue guidance for the year